Jessica R MacNeil1, Nancy Bennett2, Monica M Farley3, Lee H Harrison4, Ruth Lynfield5, Megin Nichols6, Sue Petit7, Arthur Reingold8, William Schaffner9, Ann Thomas10, Tracy Pondo11, Leonard W Mayer11, Thomas A Clark11, Amanda C Cohn11. 1. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; jmacneil@cdc.gov. 2. New York State Department of Health, Albany, New York; 3. Department of Medicine, Emory University School of Medicine and the Atlanta Veterans Affairs (VA) Medical Center, Atlanta, Georgia; 4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 5. Minnesota Department of Health, St Paul, Minnesota; 6. New Mexico Department of Health, Santa Fe, New Mexico; 7. Connecticut Department of Public Health, Hartford, Connecticut; 8. School of Public Health, University of California, Berkeley, Berkeley, California; 9. Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; and. 10. Oregon Department of Human Services, Portland, Oregon. 11. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;
Abstract
BACKGROUND: The incidence of meningococcal disease is currently at historic lows in the United States; however, incidence remains highest among infants aged <1 year. With routine use of Haemophilus influenzae type b and pneumococcal vaccines in infants and children in the United States, Neisseria meningitidis remains an important cause of bacterial meningitis in young children. METHODS: Data were collected from active, population- and laboratory-based surveillance for N meningitidis conducted through Active Bacterial Core surveillance during 2006 through 2012. Expanded data collection forms were completed for infant cases identified in the surveillance area during 2006 through 2010. RESULTS: An estimated 113 cases of culture-confirmed meningococcal disease occurred annually among infants aged <1 year in the United States from 2006 through 2012, for an overall incidence of 2.74 per 100,000 infants. Among these cases, an estimated 6 deaths occurred. Serogroup B was responsible for 64%, serogroup C for 12%, and serogroup Y for 16% of infant cases. Based on the expanded data collection forms, a high proportion of infant cases (36/58, 62%) had a smoker in the household and the socioeconomic status of the census tracts where infant meningococcal cases resided was lower compared with the other Active Bacterial Core surveillance areas and the United States as a whole. CONCLUSIONS: The burden of meningococcal disease remains highest in young infants and serogroup B predominates. Vaccines that provide long-term protection early in life have the potential to reduce the burden of meningococcal disease, especially if they provide protection against serogroup B meningococcal disease.
BACKGROUND: The incidence of meningococcal disease is currently at historic lows in the United States; however, incidence remains highest among infants aged <1 year. With routine use of Haemophilus influenzae type b and pneumococcal vaccines in infants and children in the United States, Neisseria meningitidis remains an important cause of bacterial meningitis in young children. METHODS: Data were collected from active, population- and laboratory-based surveillance for N meningitidis conducted through Active Bacterial Core surveillance during 2006 through 2012. Expanded data collection forms were completed for infant cases identified in the surveillance area during 2006 through 2010. RESULTS: An estimated 113 cases of culture-confirmed meningococcal disease occurred annually among infants aged <1 year in the United States from 2006 through 2012, for an overall incidence of 2.74 per 100,000 infants. Among these cases, an estimated 6 deaths occurred. Serogroup B was responsible for 64%, serogroup C for 12%, and serogroup Y for 16% of infant cases. Based on the expanded data collection forms, a high proportion of infant cases (36/58, 62%) had a smoker in the household and the socioeconomic status of the census tracts where infantmeningococcal cases resided was lower compared with the other Active Bacterial Core surveillance areas and the United States as a whole. CONCLUSIONS: The burden of meningococcal disease remains highest in young infants and serogroup B predominates. Vaccines that provide long-term protection early in life have the potential to reduce the burden of meningococcal disease, especially if they provide protection against serogroup B meningococcal disease.
Authors: Michael C Thigpen; Cynthia G Whitney; Nancy E Messonnier; Elizabeth R Zell; Ruth Lynfield; James L Hadler; Lee H Harrison; Monica M Farley; Arthur Reingold; Nancy M Bennett; Allen S Craig; William Schaffner; Ann Thomas; Melissa M Lewis; Elaine Scallan; Anne Schuchat Journal: N Engl J Med Date: 2011-05-26 Impact factor: 91.245
Authors: Elizabeth A Mothershed; Claudio T Sacchi; Anne M Whitney; Gwen A Barnett; Gloria W Ajello; Susanna Schmink; Leonard W Mayer; Maureen Phelan; Thomas H Taylor; Scott A Bernhardt; Nancy E Rosenstein; Tanja Popovic Journal: J Clin Microbiol Date: 2004-01 Impact factor: 5.948
Authors: Fernanda M P Rodrigues; Robin Marlow; Maria João Simões; Leon Danon; Shamez Ladhani; Adam Finn Journal: JAMA Date: 2020-12-01 Impact factor: 56.272
Authors: Lene F Lundbo; Zitta Barrella Harboe; Louise N Clausen; Mads V Hollegaard; Henrik T Sørensen; David M Hougaard; Helle B Konradsen; Mette Nørgaard; Thomas Benfield Journal: EBioMedicine Date: 2015-12-02 Impact factor: 8.143
Authors: Xuqin Chen; Yan Li; Siobhan Blankson; Min Liu; Danping Huang; H Paul Redmond; Jing Huang; Jiang Huai Wang; Jian Wang Journal: PLoS One Date: 2017-01-31 Impact factor: 3.240
Authors: Irene Rivero-Calle; Jose Gómez-Rial; Louis Bont; Bradford D Gessner; Melvin Kohn; Ron Dagan; Daniel C Payne; Laia Bruni; Andrew J Pollard; Adolfo García-Sastre; Denise L Faustman; Albert Osterhaus; Robb Butler; Francisco Giménez Sánchez; Francisco Álvarez; Myrsini Kaforou; Xabier Bello; Federico Martinón-Torres Journal: Hum Vaccin Immunother Date: 2020-08-05 Impact factor: 3.452